Locations

North Carolina

North Carolina Mesothelioma Fact Sheet

While mesothelioma is a problem in all states, the specific incident rate for North Carolina is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in NC, recent NC mesothelioma-related court cases, mesothelioma specialists in NC and potential asbestos hotspots in North Carolina.

North Carolina Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of North Carolina

North Carolina Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

North Carolina Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

North Carolina Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract:Cancer and Leukemia Group B is emerging from a clinical trials group focused on testing multiple chemotherapeutic regimens to a more selected modular concept of therapy development. Current emphasis is on answering dose intensity questions and exploring the important scientific contributions of cytogenetics, immunology and molecular biology in an effort to improve the therapy of neoplastic diseases. Our emphasis continues in the areas of lymphoma, myeloma, breast cancer, leukemia, and respiratory cancer. Bowman Gray has chaired two major studies in the lymphomas consisting of CALGB protocol #8451 and 8452. These studies are designed to test the relative effectiveness of various drugs used in the treatment of lymphomas. Results of these two studies provided the development of the successor protocol, CALGB #8556, which is AMOPLACE. Evaluation of these studies will allow us to determine the relative role of adriamycin, whether given initially or sequentially, and further explore the importance of initial intensive combination therapy versus alternating noncross-resistant treatments. Pilot studies have demonstrated the effectiveness of these treatments in refractory Hodgkin’s disease and this modular concept of combination chemotherapy has been extended to a pilot study, CALGB #8654. Bowman Gray chairs CALGB #8514, a randomized study comparing melphalan/prednisone treatment with or without alpha 2 in newly diagnosed myeloma patients. One hundred forty-six patients have accrued to this study since October 4, 1985. Pilot studies at Bowman Gray involving the combination of high-dose cytosine arabinoside and mitoxantrone will provide important information to be utilized by the group in developing subsequent leukemic studies. Our laboratory interest in drug resistance should provide important clues in the development of more effective treatments for acute leukemia. Our commitment to CALGB protocol studies is demonstrated by our accrual of 169 patients in 1986.

Tags: Neoplasms Immunization (immunotherapy), Neoplasms Of Blood And Re System, Hodgkin’s Disease, Neoplasms Of Blood And Re System, Leukemia Acute, Neoplasms Of Blood And Re System, Leukemia Lymphocytic, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Surgery, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Radiotherapy Adrenal Cortex Hormones Analogs, Prednisone, Alkaloids, Vinblastine, Alkaloids, Vincristine, Anthracenes, Mitoxantrone, Antibiotics, Anthracyclines, Adriamycin, Antibiotics, Anthracyclines, Daunomycin, Antibiotics, Antineoplastic Antibiotics, Antibiotics, Mitomycin C, Antineoplastic Agents, Azo Compounds, Hydrazines, Procarbazine, Benzo-alpha-pyrones, Warfarin, Disease Remission, Drugs, Chemotherapy, Drugs Combination, Genetic Disorders, Chromosome Abnormalities, Genetics, Cytogenetics, Haloalkylamines, Bcnu, Haloalkylamines, Ccnu, Haloalkylamines, Cyclophosphamide, Haloalkylamines, Mechlorethamine, Halopyrimidines, Halouracil, Fluorouracil, Immunity, Cytokines, Lymphokines, Interferons, Immunity, Cytokines, Monokines, Tumor Necrosis Factor, Information Gathering (data Collection), Neoplasms Classification And Staging, Neoplasms Diagnosis, Immunodiagnosis Of Neoplasms, Neoplasms Of Blood And Re System, Bone Marrow Neoplasms, Multiple Myeloma, Neoplasms Of Blood And Re System, Leukemia Myeloid, Neoplasms Of Blood And Re System, Leukemia, Hairy T-cell Leukemia, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms, Cancer Data Systems, Neoplastic Disease Epidemiology-statistics, Neoplastic Growth, Neoplasms Metastasis, Neoplastic Therapy, Cancer Chemotherapy, Hormone Therapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Pyrimidine Nucleosides, Cytosine Nucleosides, Cytosine Arabinoside, Therapy Evaluation, Human, Thiopurines, 6-mercaptopurine, Blood Transfusion, Cooperative Study Cell Sorting, Laser, Dosage And Route, Dosage, Human, Clinical

Abstract:Cancer and Leukemia Group B is emerging from a clinical trials group focused on testing multiple chemotherapeutic regimens to a more selected modular concept of therapy development. Current emphasis is on answering dose intensity questions and exploring the important scientific contributions of cytogenetics, immunology and molecular biology in an effort to improve the therapy of neoplastic diseases. Our emphasis continues in the areas of lymphoma, myeloma, breast cancer, leukemia, and respiratory cancer. Bowman Gray has chaired two major studies in the lymphomas consisting of CALGB protocol #8451 and 8452. These studies are designed to test the relative effectiveness of various drugs used in the treatment of lymphomas. Results of these two studies provided the development of the successor protocol, CALGB #8556, which is AMOPLACE. Evaluation of these studies will allow us to determine the relative role of adriamycin, whether given initially or sequentially, and further explore the importance of initial intensive combination therapy versus alternating noncross-resistant treatments. Pilot studies have demonstrated the effectiveness of these treatments in refractory Hodgkin’s disease and this modular concept of combination chemotherapy has been extended to a pilot study, CALGB #8654. Bowman Gray chairs CALGB #8514, a randomized study comparing melphalan/prednisone treatment with or without alpha 2 in newly diagnosed myeloma patients. One hundred forty-six patients have accrued to this study since October 4, 1985. Pilot studies at Bowman Gray involving the combination of high-dose cytosine arabinoside and mitoxantrone will provide important information to be utilized by the group in developing subsequent leukemic studies. Our laboratory interest in drug resistance should provide important clues in the development of more effective treatments for acute leukemia. Our commitment to CALGB protocol studies is demonstrated by our accrual of 169 patients in 1986.

Tags: Neoplasms Immunization (immunotherapy), Neoplasms Of Blood And Re System, Hodgkin’s Disease, Neoplasms Of Blood And Re System, Leukemia Acute, Neoplasms Of Blood And Re System, Leukemia Lymphocytic, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Surgery, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Radiotherapy Adrenal Cortex Hormones Analogs, Prednisone, Alkaloids, Vinblastine, Alkaloids, Vincristine, Anthracenes, Mitoxantrone, Antibiotics, Anthracyclines, Adriamycin, Antibiotics, Anthracyclines, Daunomycin, Antibiotics, Antineoplastic Antibiotics, Antibiotics, Mitomycin C, Antineoplastic Agents, Azo Compounds, Hydrazines, Procarbazine, Benzo-alpha-pyrones, Warfarin, Disease Remission, Drugs, Chemotherapy, Drugs Combination, Genetic Disorders, Chromosome Abnormalities, Genetics, Cytogenetics, Haloalkylamines, Bcnu, Haloalkylamines, Ccnu, Haloalkylamines, Cyclophosphamide, Haloalkylamines, Mechlorethamine, Halopyrimidines, Halouracil, Fluorouracil, Immunity, Cytokines, Lymphokines, Interferons, Immunity, Cytokines, Monokines, Tumor Necrosis Factor, Information Gathering (data Collection), Neoplasms Classification And Staging, Neoplasms Diagnosis, Immunodiagnosis Of Neoplasms, Neoplasms Of Blood And Re System, Bone Marrow Neoplasms, Multiple Myeloma, Neoplasms Of Blood And Re System, Leukemia Myeloid, Neoplasms Of Blood And Re System, Leukemia, Hairy T-cell Leukemia, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms, Cancer Data Systems, Neoplastic Disease Epidemiology-statistics, Neoplastic Growth, Neoplasms Metastasis, Neoplastic Therapy, Cancer Chemotherapy, Hormone Therapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Pyrimidine Nucleosides, Cytosine Nucleosides, Cytosine Arabinoside, Therapy Evaluation, Human, Thiopurines, 6-mercaptopurine, Blood Transfusion, Cooperative Study Cell Sorting, Laser, Dosage And Route, Dosage, Human, Clinical

  • Followup Grant: 5U10CA003927-33
  • Followup Grant: 5U10CA003927-34
  • Followup Grant: 2U10CA003927-36
  • Followup Grant: 5U10CA003927-37
  • Followup Grant: 5U10CA003927-38
  • Followup Grant: 5U10CA003927-40

Abstract: Asbestos has long been known to cause primary lung cancer, mesothelioma, pleuropulmonary fibrosis, and pleural effusions in humans and experimental animals. Many studies have focused on fiber-induced fibroproliferative and inflammatory processes in the lung; however, very few studies have examined alterations in the pleural space, an important target site of fiber-induced disease. Pleural inflammation is a common feature of asbestos-related disease, but little is known about the factors that regulate this process. Therefore the objective of this proposal is to determine the role of pleural mesothelial cell adhesion molecules in mineral fiber-induced inflammation. This research is designed to test the hypothesis that alterations in pleural mesothelial cell adhesion molecule expression correlate with inflammation. The research design involves using in vivo and in vitro techniques to determine pleural mesothelial cell adhesion molecule expression following asbestos exposure. Specific aims are to (1) determine if there are alterations in intercellular adhesion molecule-1 (ICAM1) and vascular adhesion molecule-1 (VCAM-1) expression following mineral fiber exposure; (2) determine if these alterations are particle-type specific; and to (3) determine if these alterations are dependent upon direct interaction of mineral fibers with target cells or mediated by indirect factors. The results of this work will provide the first description of adhesion molecule expression in pleural mesothelial cells from the rat, the animal model most commonly used in fiber toxicology. These data will provide new information concerning mechanisms of inflammation in the pleural space.

Tags: Asbestos, Cell Adhesion Molecule, Disease Model, Environmental Toxicology, Inflammation, Lung Injury Pleural Cavity Effusion, Titanium Immunofluorescence Technique, Laboratory Rat, Western Blotting

  • Followup Grant: 5F32ES005811-02
  • Followup Grant: 5F32ES005811-03

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Cervical Cancer; Fallopian Tube Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Ovarian Cancer; Pancreatic Cancer; Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information

Hospitals and Cancer Centers

Comprehensive Cancer Center at Wake Forest University

Medical Center Boulevard
Winston-Salem, NC
336.716.2088

Physicians

Dr. David H. Harpole, Jr.
Associate Professor of Surgery
Duke University Medical Center
DUMC Box 3617
3582 Duke Hospital South
Durham, NC 27710
(919) 684-3683
harpo002@mc.duke.edu

Edward Levine, M.D.
Wake Forest University Baptist Medical Center
Medical Center Boulevard
Winston Salem, NC 27157
(336) 716-4276

Williams v. CSX Transp., Inc.
NO. COA05-488 , COURT OF APPEALS OF NORTH CAROLINA, January 9, 2006, Heard In The Court Of Appeals , March 7, 2006, Filed

Payne v. Charlotte Heating & Air Conditioning
NO. COA03-1651 , COURT OF APPEALS OF NORTH CAROLINA, October 12, 2004, Heard In The Court Of Appeals , August 16, 2005, Filed

Lackey v. Sears Roebuck & Co.
NO. COA03-47 , COURT OF APPEALS OF NORTH CAROLINA, November 12, 2003, Heard In The Court Of Appeals , December 16, 2003, Filed

Robbins v. Wake County Bd. of Educ.
NO. COA01-1224, COURT OF APPEALS OF NORTH CAROLINA, June 11, 2002, Heard In The Court Of Appeals , July 16, 2002, Filed

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

Name (required)

State (required)

Your Email (required)

Phone

Navigation